Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Subscribe To Our Newsletter & Stay Updated